Amneal Pharmaceuticals, Inc. AMRX Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Amneal Pharmaceuticals, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Amneal Pharmaceuticals, Inc.’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s return on equity?
- Amneal Pharmaceuticals, Inc. (AMRX) reported return on equity of -52.8% in Q4 2023.
- How has Amneal Pharmaceuticals, Inc.'s return on equity changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s return on equity increased by 31.8% year-over-year, from -77.4% to -52.8%.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s return on equity?
- Over 2 years (2020 to 2023), Amneal Pharmaceuticals, Inc.'s return on equity has grown at a 22.5% compound annual growth rate (CAGR), from 35.2% to -52.8%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.